.jpeg)
Entrectinib latest news on the market
Entrectinib (Entrectinib), trade name Rozlytrek, is an anti-cancer drug used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It was approved for marketing use in the United States by the U.S. Food and Drug Administration (FDA) in August 2019, in Australia in May 2020, and in the European Union in July 2020 by the European Medicines Agency (EMA) for medical use. The original drug entrectinib was approved by China’s State Food and Drug Administration for marketing in China in 2022. However, due to its short time on the market, it has not yet been included in the medical insurance catalog.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
